Skip to content

Multi-dimensional Signatures for Precisely Predicting the Response and Prognosis of Lung Cancer Patients

Multi-dimensional Signatures for Precisely Predicting the Response and Prognosis of Lung Cancer Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04980352
Acronym
Pred-lung
Enrollment
200
Registered
2021-07-28
Start date
2021-01-01
Completion date
2024-12-30
Last updated
2021-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prognosis, Response

Keywords

Multi-dimensional Signatures, NGS, Lung Cancer

Brief summary

This study aims to determine the clinical effectiveness of multi-dimensional signatures in predicting response and prognosis of lung cancer patients. The study is a multi-center perspective research of treatment planning for patients with lung cancer. To characterize clinical effectiveness, the progression-free survival (PFS) and overall survival (OS) impacts of multi-dimensional signatures will be estimated.

Detailed description

Multi-dimensional signatures, including NGS-based genotyping, and other essential detections such as immunohistochemistry (IHC), provides an opportunity to improve outcomes for patients by tailoring treatments to each individual's genomic profile. This is a multi-center single arm research study integrating multi-dimensional signatures into clinical decision-making for patients with lung cancer. The clinical effectiveness of multi-dimensional signatures is unknown in the real-world of clinics. To identify a counterfactual for Pred-lung approach, matching methods combined with administrative healthcare data will be used. The survival impacts of Pred-lung approach compared to usual care in matched controls will then be estimated.

Interventions

OTHERreal world treatment by doctors

real world treatment by doctors

Sponsors

Renmin Hospital of Wuhan University
CollaboratorOTHER
Wuhan TongJi Hospital
CollaboratorOTHER
Wuhan University
CollaboratorOTHER
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with locally-advanced or metastasis lung cancer * Life expectancy \> 3 months

Exclusion criteria

* Age at diagnosis \<18 * refuse to enroll

Design outcomes

Primary

MeasureTime frameDescription
PFSthrough study completion, an average of 6 monthsProgression-free survival

Secondary

MeasureTime frameDescription
OSthrough study completion, an average of 1 yearOverall survival

Countries

China

Contacts

Primary ContactYuan Li, Dr.
liyuanpumc@gmail.com+862788041911

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026